Positive News SentimentPositive NewsNASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis $10.60 -0.03 (-0.28%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avadel Pharmaceuticals Stock (NASDAQ:AVDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avadel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$10.60▼$11.0350-Day Range$8.81▼$11.2552-Week Range$6.38▼$17.30Volume427,149 shsAverage Volume1.34 million shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$18.33Consensus RatingBuy Company Overview Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Read More Avadel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreAVDL MarketRank™: Avadel Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 571st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 14.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.78% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 19.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.78% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 19.02%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentAvadel Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avadel Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest3 people have searched for AVDL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 21, 2025 | globenewswire.comHC Wainwright Initiates Coverage on Avadel Pharmaceuticals (NASDAQ:AVDL)July 20, 2025 | americanbankingnews.comAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.July 30 at 2:00 AM | Mode Mobile (Ad)ASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersJuly 14, 2025 | businesswire.comBullish Avadel Pharmaceuticals Insiders Loaded Up On US$761.7k Of StockJuly 7, 2025 | finance.yahoo.comJazz Pharmaceuticals: I See Big Potential In This Stock As An InvestorJuly 7, 2025 | seekingalpha.comAVDL Avadel Pharmaceuticals plc - Seeking AlphaJuly 5, 2025 | seekingalpha.comAvadel announces appeals court decision upholding FDA approval of LUMRYZJune 30, 2025 | msn.comSee More Headlines AVDL Stock Analysis - Frequently Asked Questions How have AVDL shares performed this year? Avadel Pharmaceuticals' stock was trading at $10.51 on January 1st, 2025. Since then, AVDL shares have increased by 2.9% and is now trading at $10.82. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The company's revenue was up 93.2% compared to the same quarter last year. Read the conference call transcript. Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' top institutional investors include Wealth Effects LLC (2.43%), Investors Asset Management of Georgia Inc. GA ADV (0.14%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.02%) and KLP Kapitalforvaltning AS (0.02%). Insiders that own company stock include Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX). Company Calendar Last Earnings5/07/2025Today7/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVDL CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees70Year Founded2015Price Target and Rating Average Price Target for Avadel Pharmaceuticals$18.33 High Price Target$30.00 Low Price Target$12.00 Potential Upside/Downside+69.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.83 million Net Margins-13.58% Pretax Margin-13.72% Return on Equity-36.07% Return on Assets-16.30% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.33 Sales & Book Value Annual Sales$194.45 million Price / Sales5.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book14.05Miscellaneous Outstanding Shares96,739,000Free Float91,709,000Market Cap$1.05 billion OptionableOptionable Beta1.42 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:AVDL) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.